Cybin to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
Cybin Inc. Common Shares (CYBN)
Company Research
Source: Business Wire
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Amir Inamdar, Cybin’s Chief Medical Officer, will participate in a panel discussion at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit taking place virtually on September 26, 2024.The panel discussion, titled “Advancement in Psychedelic Therapies for Neuropsychiatry,” will be webcast live on Thursday, September 26, 2024, at 10:00 a.m. ET. To listen to the event, please click here to access the webcast. The archived webcast will also be available on the Company’s investor relations website on the Events & Presentations page.About CybinCybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative
Show less
Read more
Impact Snapshot
Event Time:
CYBN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CYBN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYBN alerts
High impacting Cybin Inc. Common Shares news events
Weekly update
A roundup of the hottest topics
CYBN
News
- Water Tower Research Publishes Initiation of Coverage Report on Cybin, Inc., “A Leader in Novel Neuropsychiatry Therapeutics” [Yahoo! Finance]Yahoo! Finance
- Cybin Inc. (NYSE: CYBN) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $114.00 to $96.00. They now have a "buy" rating on the stock.MarketBeat
- Cybin Provides Corporate Update on Upcoming Clinical Milestones [Yahoo! Finance]Yahoo! Finance
- Cybin Provides Corporate Update on Upcoming Clinical MilestonesBusiness Wire
- 'We're Pretty Cheap At The Moment' - Cybin CEO Doug Drysdale [Seeking Alpha]Seeking Alpha
CYBN
Earnings
- 6/26/24 - Miss
CYBN
Sec Filings
- 9/24/24 - Form 6-K
- 9/20/24 - Form 6-K
- 9/20/24 - Form 6-K
- CYBN's page on the SEC website